TY - JOUR
T1 - Intra-arterial Chemotherapy for Head and Neck Cancer
T2 - An Update on the Totally Implantable Infusion Pump
AU - Baker, Shan R.
AU - Forastiere, Arlene A.
AU - Wheeler, Richard
AU - Medvec, Barbara R.
PY - 1987/11
Y1 - 1987/11
N2 - Intra-arterial chemotherapy for the treatment of localized malignant neoplasms in the head and neck is an appealing approach for several reasons. Perhaps the most important is the possibility of obtaining a regional advantage such that an increased drug concentration is delivered to the tumor site compared with that delivered systemically. The patient may, therefore, be spared systemic toxicity. We report our accumulated experience using a totally implantable infusion pump in 37 patients. A total of 42 pumps were implanted: 28 single-catheter pumps and 14 dual-catheter pumps. Radionuclide imaging demonstrated total perfusion of the tumor in all patients. A combination of cisplatin (50 to 100 mg/m2) and floxuridine (0.01 to 0.045 mg/kg/d) was used to treat 26 patients. For these heavily pretreated patients, we observed a 43% complete and partial response rate in the subgroup of patients with squamous cell carcinoma. These results are comparable with those reported for these drugs administered systemically and for other drug combinations tested in the treatment of recurrence disease.
AB - Intra-arterial chemotherapy for the treatment of localized malignant neoplasms in the head and neck is an appealing approach for several reasons. Perhaps the most important is the possibility of obtaining a regional advantage such that an increased drug concentration is delivered to the tumor site compared with that delivered systemically. The patient may, therefore, be spared systemic toxicity. We report our accumulated experience using a totally implantable infusion pump in 37 patients. A total of 42 pumps were implanted: 28 single-catheter pumps and 14 dual-catheter pumps. Radionuclide imaging demonstrated total perfusion of the tumor in all patients. A combination of cisplatin (50 to 100 mg/m2) and floxuridine (0.01 to 0.045 mg/kg/d) was used to treat 26 patients. For these heavily pretreated patients, we observed a 43% complete and partial response rate in the subgroup of patients with squamous cell carcinoma. These results are comparable with those reported for these drugs administered systemically and for other drug combinations tested in the treatment of recurrence disease.
UR - http://www.scopus.com/inward/record.url?scp=0023568282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023568282&partnerID=8YFLogxK
U2 - 10.1001/archotol.1987.01860110049007
DO - 10.1001/archotol.1987.01860110049007
M3 - Article
C2 - 3663345
AN - SCOPUS:0023568282
SN - 0886-4470
VL - 113
SP - 1183
EP - 1190
JO - Archives of Otolaryngology--Head and Neck Surgery
JF - Archives of Otolaryngology--Head and Neck Surgery
IS - 11
ER -